Rigel Pharmaceuticals reported $121K in Cost of Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Agenus AGEN:US $ 543K 338K
Amgen AMGN:US $ 1561M 157M
Anika Therapeutics ANIK:US $ 14.89M 2.8M
AstraZeneca AZN:LN 2279M 790M
Astrazeneca AZN:US 2.28B 790M
Biomarin Pharmaceutical BMRN:US $ 116.96M 2.78M
Bristol Myers Squibb BMY:US $ 2471M 115M
ChemoCentryx CCXI:US 205K 97K
Daiichi Sankyo 4568:JP Y 88830M 3109M
Eli Lilly And LLY:US $ 2072.1M 21.9M
Halozyme Therapeutics HALO:US $ 15.92M 5.66M
Heron Therapeutics HRTX:US $ 11.36M 0.41M
Intrexon XON:US $ 17.1M 2.17M
Karyopharm Therapeutics KPTI:US $ 1.43M 684K
Ligand Pharmaceuticals LGND:US $ 4.7M 7.28M
MacroGenics MGNX:US 48K 899K
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Pfizer PFE:US $ 10010M 399M
Regeneron Pharmaceuticals REGN:US $ 404.9M 577.7M
Rigel Pharmaceuticals RIGL:US $ 0.12M 0.37M
Ultragenyx Pharmaceutical RARE:US $ 6.1M 2.59M
Veracyte VCYT:US $ 23.71M 0.83M